Clinical proteomics: Applications for prostate cancer biomarker discovery and detection.
The science of proteomics comprises much more than simply generating lists of proteins that change in expression as a cause of or consequence of pathophysiology. The goal of proteomics should be to characterize the information flow through the intercellular protein circuitry that communicates with the extracellular microenvironment and then ultimately to the serum/plasma macroenvironment. Serum proteomic pattern diagnostics is a new type of proteomic concept in which patterns of ion signatures generated from high dimensional mass spectrometry data are used as diagnostic classifiers. This recent approach has exciting potential for clinical utility of diagnostic patterns because low molecular weight metabolites, peptides, and protein fragments may have higher accuracy than traditional biomarkers of cancer detection. Intriguingly, we now have discovered that this diagnostic information exists in a bound state, complexed with circulating highly abundant carrier proteins. These diagnostic fragments may one day be harvested by circulating nanoparticles, designed to absorb, enrich, and amplify the repertoire of diagnostic biomarkers generated-even at the critical, initial stages of carcinogenesis.
FDA-NCI Clinical Proteomics Program, Office of Cell and Gene Therapies, Center for Biologic Evaluation and Research, Food and Drug Administration, Bethesda, MD 20892, USA. petricoin@cber.fda.gov
Emanuel F
EF
Petricoin
David K
DK
Ornstein
Lance A
LA
Liotta
D014408:Biomarkers, Tumor / Q000032:analysis*; D003937:Diagnosis, Differential; D020869:Gene Expression Profiling; D006801:Humans; D008297:Male; D013058:Mass Spectrometry; D011471:Prostatic Neoplasms / Q000175:diagnosis* / Q000503:physiopathology*; D040081:Protein Array Analysis; D040901:Proteomics / Q000639:trends*
D014408:Biomarkers, Tumor